regression of esophageal varices during entecavir treatment in patients with hepatitis-b-virus-related liver cirrhosis

Clicks: 330
ID: 153838
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #11 of 17 articles by views in american journal of clinical oncology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Recent studies suggest that liver cirrhosis is reversible after administering oral nucleos(t)ide analogue therapy to patients with hepatitis B virus (HBV) infection. However, few studies have addressed whether esophageal varices can regress after such therapy. We report a case of complete regression of esophageal varices during entecavir therapy in patients with HBV-related liver cirrhosis, suggesting that complications of liver cirrhosis such as esophageal varices can regress after the long-term suppression of HBV replication.
Reference Key
jwa2016clinicalregression Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hye Young Jwa, Yoo-Kyung Cho, Eun Kwang Choi, Heung Up Kim, Hyun Joo Song, Soo-Young Na, Sun-Jin Boo, Seung Uk Jeong, Bong Soo Kim, Byoung-Wook Lee, Byung-Cheol Song
Are you one of these authors? Claim your profile
Journal american journal of clinical oncology
Year 2016
DOI
10.3350/cmh.2016.22.1.183
URL
http://e-cmh.org/upload/pdf/cmh-22-1-183.pdf
Keywords
hepatitis b virus Gastroenterology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.